Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

First insights into community pharmacy based buprenorphine-naloxone dispensing in Finland.

Uosukainen H, Bell JS, Laitinen K, Tacke U, Ilomäki J, Turunen JH.

Int J Drug Policy. 2013 Sep;24(5):492-7. doi: 10.1016/j.drugpo.2013.02.004. Epub 2013 Apr 6.

PMID:
23567099
2.

Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/ naloxone to patients with opioid dependence.

Raisch DW, Fudala PJ, Saxon AJ, Walsh R, Casadonte P, Ling W, Johnson BA, Malkerneker U, Ordorica P, Williford WO, Sather MR.

J Am Pharm Assoc (2003). 2005 Jan-Feb;45(1):23-32.

PMID:
15730114
3.

The impact of community pharmacy dispensing fees on the introduction of buprenorphine - naloxone in Australia.

Winstock AR, Lea T, Ritter A.

Drug Alcohol Rev. 2007 Jul;26(4):411-6.

PMID:
17564877
4.

Community pharmacy services for people with drug problems over two decades in Scotland: Implications for future development.

Matheson C, Thiruvothiyur M, Robertson H, Bond C.

Int J Drug Policy. 2016 Jan;27:105-12. doi: 10.1016/j.drugpo.2015.11.006. Epub 2015 Nov 27.

PMID:
26723885
5.

Problems experienced by community pharmacists delivering opioid substitution treatment in New South Wales and Victoria, Australia.

Winstock AR, Lea T, Sheridan J.

Addiction. 2010 Feb;105(2):335-42. doi: 10.1111/j.1360-0443.2009.02774.x.

PMID:
20078490
7.

Buprenorphine supply by community pharmacists in Victoria, Australia: perceptions, experiences and key issues identified.

Nielsen S, Dietze P, Dunlop A, Muhleisen P, Lee N, Taylor D.

Drug Alcohol Rev. 2007 Mar;26(2):143-51.

PMID:
17364849
8.

What is diversion of supervised buprenorphine and how common is it?

Winstock AR, Lea T, Sheridan J.

J Addict Dis. 2009 Jul;28(3):269-78. doi: 10.1080/10550880903028841.

PMID:
20155596
9.

[Substitution treatment for opiate dependence: survey of community pharmacies in Aquitaine].

Jeantaud I, Haramburu F, Bégaud B.

Therapie. 1999 Mar-Apr;54(2):251-5. French.

PMID:
10394262
10.

Pharmacists' role in the continued care of patients under opiate substitution treatment.

Messaadi N, Pansu A, Cohen O, Cottencin O.

Therapie. 2013 Nov-Dec;68(6):393-400. doi: 10.2515/therapie/2013059. Epub 2013 Nov 11.

PMID:
24246120
11.

A system approach to dispensing errors: a national study on perceptions of the Finnish community pharmacists.

Teinilä T, Grönroos V, Airaksinen M.

Pharm World Sci. 2008 Dec;30(6):823-33. doi: 10.1007/s11096-008-9233-4. Epub 2008 Jun 24.

PMID:
18574708
13.

Dispensing opioid substitution treatment: practices, attitudes and intentions of community-based pharmacists.

Lawrinson P, Roche A, Terao H, Le PP.

Drug Alcohol Rev. 2008 Jan;27(1):47-53.

PMID:
18034381
14.

Opinion comparison concerning future information technology in Finnish community pharmacies.

Westerling AM, Hynninen JT, Haikala VE, Airaksinen MS.

Pharm World Sci. 2010 Dec;32(6):787-94. doi: 10.1007/s11096-010-9438-1. Epub 2010 Sep 17.

PMID:
20848207
15.

Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients.

Larance B, Degenhardt L, O'Brien S, Lintzeris N, Winstock A, Mattick RP, Bell J, Ali R.

Drug Alcohol Rev. 2011 Nov;30(6):613-20. doi: 10.1111/j.1465-3362.2010.00274.x. Epub 2011 Jan 5.

PMID:
21355939
16.

Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.

Bailey AM, Wermeling DP.

Ann Pharmacother. 2014 May;48(5):601-6. doi: 10.1177/1060028014523730. Epub 2014 Feb 12.

17.

Consumer satisfaction with opioid treatment services at community pharmacies in Australia.

Lea T, Sheridan J, Winstock A.

Pharm World Sci. 2008 Dec;30(6):940-6. doi: 10.1007/s11096-008-9257-9. Epub 2008 Oct 11.

PMID:
18850299
18.

Use and misuse of opioid replacement therapies: a Queensland study.

Smirnov A, Kemp R.

Subst Use Misuse. 2012 Jan;47(1):78-85. doi: 10.3109/10826084.2011.629017.

PMID:
22216993
19.

[Changes in psychosocial symptoms of opiate users over six months with buprenorphine/naloxone substitution therapy].

Petke Z, Csorba J, Meszaros J, Vingender I, Farkas J, Demetrovics Z, Kovacs Z, Menczel Z, Pataki Z, Simor P, Havasi A, Melles K, Marvanykovi F, Racz J.

Neuropsychopharmacol Hung. 2012 Mar;14(1):7-17. Hungarian.

20.

Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.

Fiellin DA, Pantalon MV, Chawarski MC, Moore BA, Sullivan LE, O'Connor PG, Schottenfeld RS.

N Engl J Med. 2006 Jul 27;355(4):365-74.

Supplemental Content

Support Center